GenSight Biologics Confirms Full-Year 2025 Financial Results in Line with Prior Estimates
GenSight Biologics a clinical-stage biopharmaceutical company specializing in innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, has confirmed that its final consolidated financial results for the fiscal year ended December 31, 2025, align with the preliminary figures released on March 27, 2026.
Confirmation of Financial Results
The Company announced that its Board of Directors has approved the definitive consolidated and statutory financial statements, which validate the previously disclosed estimated figures. The financial performance reflects continued operational discipline, although the Company remains in a loss-making stage typical of clinical-stage biotech firms.
For the year 2025, GenSight reported total operating income of €0.7 million, unchanged from its estimated figures but significantly lower than €2.6 million recorded in 2024. The decline primarily reflects reduced revenues and lower levels of other income.
Operating loss improved to €11.1 million compared to €15.8 million in 2024, demonstrating a notable reduction in operating expenses. Financial loss stood at €1.0 million, compared to a financial gain of €1.8 million in the prior year. Overall, the Company reported a net loss of €12.0 million, slightly improved from €14.0 million in 2024.
Cash and cash equivalents totaled €2.4 million as of December 31, 2025, remaining relatively stable compared to €2.5 million in 2024. Total liabilities decreased to €33.2 million from €37.7 million, while shareholders’ equity remained negative at €24.9 million.
Audit Status and Financial Reporting
The audit process for both consolidated and individual financial statements is currently underway. GenSight expects its statutory auditors to issue their reports following completion of procedures required for filing its Universal Registration Document with the French financial regulator, the Autorité des Marchés Financiers (AMF).
Going Concern Considerations
The financial statements have been prepared on a going concern basis. However, management acknowledges that this assumption depends on the Company’s ability to secure additional funding and generate sufficient revenues.
No adjustments have been made to asset valuations or liability classifications that would otherwise be necessary if the Company were unable to continue operations. Nonetheless, management has highlighted significant uncertainties that could affect its future financial stability.
Liquidity Position and Recent Financing Activities
As of March 31, 2026, GenSight reported cash and cash equivalents of €3.2 million, reflecting an increase from €2.4 million at year-end 2025.
Throughout 2025 and early 2026, the Company raised approximately €15.7 million through multiple equity financing transactions. These included the issuance of shares and warrants subscribed by both existing investors—such as Heights Capital, Sofinnova, Invus, UPMC Enterprises, and Alumni Capital—and new investors.
Despite these capital inflows, the Company has indicated that its current financial resources are insufficient to meet operational requirements over the next 12 months without additional funding.
Financial Obligations
As of December 31, 2025, GenSight’s financial debt totaled €22.9 million. This includes:
- €9.4 million under Tranche A of a European Investment Bank (EIB) loan, repayable in a single payment in February 2028.
- €6.3 million in convertible bonds issued to Heights Capital, with quarterly repayments continuing through December 2027.
- €7.2 million in conditional advances from Bpifrance, with repayments beginning in June 2026.
Additionally, the Company has a €5.0 million refund liability linked to potential rebates under its early access program, payable upon future marketing authorization.
Business Update
In December 2025, GenSight achieved a significant milestone when the French National Agency for Medicines and Health Products Safety (ANSM) granted Compassionate Use Authorization for its lead gene therapy candidate, GS010 (LUMEVOQ®). This authorization allows eligible patients to access the treatment prior to formal regulatory approval.
In March 2026, the first patients were treated under this program at the 15–20 National Hospital in Paris, marking the beginning of revenue generation from early access programs. Initial payments were received by the end of March 2026.
Although the exact timing and volume of treatments remain uncertain, management expects that revenues from early access programs in France and Israel during 2026 will be sufficient to cover operating expenses, excluding costs associated with the planned Phase III clinical trial.
Outlook and Funding Strategy
While early access revenues are expected to support near-term operations, they will not fully fund the Company’s planned RECOVER Phase III clinical trial for GS010, which is anticipated to begin in the second quarter of 2027.
To address this funding gap, GenSight is exploring several strategic options, including:
- Additional equity or debt financing
- Expansion of early access programs into new international markets
- Licensing agreements outside the United States and Europe
- Strategic partnerships or mergers and acquisitions
The Company aims to secure sufficient funding before the end of 2026 to avoid delays in its clinical development timeline.
Going Concern Assessment
Management’s assessment of the Company’s ability to continue as a going concern is based on cash flow projections covering at least 12 months from the date of approval of the financial statements.
These projections assume:
- Successful execution of early access programs generating sufficient operating revenue in 2026
- Availability of short-term bridge financing if needed
- Ability to secure additional funding through various strategic avenues
- Timely manufacturing scale-up to support future treatment demand
Despite these assumptions, management acknowledges that there is no guarantee that funding will be secured in a timely manner or on favorable terms. Failure to do so could lead to delays in operations, asset impairment, or potential insolvency.
Financial Performance Details
GenSight’s revenue declined sharply to €1,000 in 2025 from €1.5 million in 2024, reflecting reduced commercial activity. Other income also decreased by 42% to €651,000.
However, the Company significantly reduced operating expenses to €11.7 million from €18.4 million in the previous year. Research and development expenses dropped by nearly 48%, while general and administrative costs declined by 12.5%.
Net cash used in operating activities improved to €9.2 million compared to €12.9 million in 2024, reflecting tighter cost management.
Balance Sheet Overview
Total assets decreased to €8.3 million from €10.8 million in 2024, driven by reductions in both current and non-current assets. Shareholders’ equity remained negative due to accumulated losses, although capital increases during the year helped partially offset this deficit.
The Company issued over 93 million new shares in 2025, raising additional capital, along with the exercise of convertible bonds and share-based compensation instruments.
Upcoming Events
GenSight Biologics plans to report its cash position as of March 31, 2026, on April 7, 2026. The Company will also hold its Annual General Meeting on May 19, 2026.
About GenSight Biologics
GenSight Biologics is focused on developing gene therapies aimed at preserving or restoring vision in patients suffering from retinal diseases. Its lead candidate, GS010 (lenadogene nolparvovec), targets Leber Hereditary Optic Neuropathy (LHON), a rare genetic disorder that causes rapid and irreversible vision loss.
The Company leverages proprietary platforms such as Mitochondrial Targeting Sequence (MTS) and optogenetics to develop transformative treatments. Its therapies are designed as single-administration injections to provide long-lasting benefits.
Forward-Looking Statements
This release includes forward-looking statements related to financial projections, clinical development, and strategic initiatives. These statements involve risks and uncertainties, and actual results may differ materially.
Investors are advised to consult GenSight’s regulatory filings with the AMF for detailed risk disclosures and not to rely solely on forward-looking statements.
About GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. GS010 is currently in clinical development, has not to date been granted marketing authorization in France or any other jurisdiction, and is therefore not available commercially. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
